期刊文献+

骨肉瘤细胞和组织H3K27me3表达与临床病理特征相关性研究 被引量:1

Expression of H3K27me3 in osteosarcoma and its relationship with clinicopathological characteristics
原文传递
导出
摘要 目的组蛋白H3K27三甲基化(H3K27me3)在肿瘤发生发展过程中起着重要作用,研究发现H3K27me3在肝癌和前列腺癌等恶性肿瘤中的表达和临床病理特征存在相关性,但其在骨肉瘤中的研究相对较少。本研究分析H3K27me3在骨肉瘤细胞和组织中的表达及其与临床病理的关系,并探讨H3K27me3在骨肉瘤发生和发展中的作用和意义。方法所有切片均来自于河北医科大学第四医院骨科2005-01-01-2011-01-01手术切除的标本。采用蛋白印迹法检测骨肉瘤MG-63、U2-OS、Sa-OS细胞系及hFOB1.19成骨细胞中H3K27me3表达的水平差异;采用免疫组织化学染色方法检测53例骨肉瘤组织及16例骨软骨瘤组织中H3K27me3的表达水平。Kaplan-Meier分析比较H3K27me3高表达和低表达患者生存率之间的差异。并应用Cox回归模型分析其表达水平对预后影响。结果hFOB1.19、MG-63、U2-OS和Sa-OS中H3K27me3蛋白表达水平分别为0.37±0.06、0.86±0.06、0.79±0.07和0.83±0.05,与hFOB1.19细胞中H3K27me3表达相比,3组骨肉瘤细胞系中H3K27me3蛋白表达水平均显著升高,P=0.023;与骨软骨瘤组织相比(56.3%),H3K27me3在骨肉瘤组织中高表达(84.9%),二者差异有统计学意义(P<0.001),并与肿瘤大小、肺转移、Enneking分期和生存率有关,P值分别为0.037、0.020、0.023和0.046。且其表达水平与患者生存期显著相关,P=0.012。结论 H3K27me3在骨肉瘤细胞及骨肉瘤组织中呈高表达,并与肿瘤的临床病理特征相关,可能会是骨肉瘤患者重要的预后因子及治疗靶点。 OBJECTIVE H3K27me3 plays an important role in the development of tumor.Previous studies have found that there is a correlation between the expression of H3K27me3 and pathological characteristics in liver and prostate cancer and other malignant tumors.However,the research about osteosarcoma is relatively less.The aims of this study were to investigate the expression of H3K27me3 in osteosarcoma tissue and cell lines and to evaluate its correlation with clinicopathological parameters of osteosarcoma and to study the role of H3K27me3 in the initiation and progression of osteosarcoma.METHODS All slices were from the department of orthopedics,the Fourth Hospital of Hebei Medical University,2005-01-01 to 2011-01-01.The protein expression of H3K27me3 was detected by Western blot in osteosarcoma cell lines MG-63,U2-OS,Sa-OS and human osteoblast cell hFOB1.19.Immunohistochemistry(IHC)was utilized to examine the protein expression of H3K27me3 in 53osteosarcoma specimens and 16 osteochondroma specimens.Differences between survival curves were assessed for statistical significance with the log-rank test.The Cox regression model was used to analyze the effect of H3K27me3 expression level on the prognosis of the patients.RESULTS In hFOB1.19,MG-63,U2-OS,Sa-OS,H3K27me3 protein expression levels were 0.37±0.06,0.86±0.06,0.79±0.07 and 0.83±0.05.Compared with hFOB1.19 cell,H3K27me3protein expression levels were significantly increased(P=0.023).Compared with chondrosarcoma(56.3%),the high expression of H3K27me3 was significant higher in osteosarcoma tissues(84.9%).The expression levels of H3K27me3 were significantly associated with tumor size,metastasis,Enneking stage,shorter overall survival(Pvalues were 0.037,0.020,0.023 and 0.046,respectively)and its expression level was significantly correlated with the survival time of the patients(P=0.012).CONCLUSIONS H3K27me3 is highly expressed in osteosarcoma cells and osteosarcoma tissues,and correlates closely to the clinical and pathological features.It may be an important prognostic factor and therapeutic target for osteosarcoma therapy.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2016年第22期1488-1492,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 河北省卫生厅医学科学研究重点课题计划(20160159) 河北省自然基金面上项目(H2015206314)
关键词 组蛋白修饰 H3K27me3 骨肉瘤 预后 histone modification H3K27me3 osteosarcoma prognosis
  • 相关文献

参考文献2

二级参考文献42

  • 1Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity[J]. J Biol,2008,7(2) :6.
  • 2Chen H, Rossier C, Antonarakis S E. Cloning of a human hom olog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2[J]. Genomics,1996,38(38):30-37.
  • 3Kahn T G, Schwartz Y B, Dellino G I, et al. Polycomb complexes and the propagation of the methylation mark at the Drosophila ubx gene[J]. J Biol Chem,2006,281(39) :29064-29075.
  • 4Ezhkova E, Pasolli H A, Parker J S, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells[J]. Cell,2009,136(6) :1122-1135.
  • 5Richter G H, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation[J]. Proc Natl Acad Sci U S A,2009,106(13):5324-5329.
  • 6Cardoso C, Timsit S, Villard L, et al. Specific interaction between the XNP/ATR-X gene product and the SET domain of the humanEZH2 protein[J]. Hum Mol Genet,1998,7(4):679-684.
  • 7Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders[J]. Eur J Hum Genet,2000,8(3) :174-180.
  • 8Arisan S, Buyuktuncer E D, Palavan-Unsal N, et al. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma[J]. Urol Int,2005,75(3):252-257.
  • 9Qian C, Zhou M M. SET domain protein lysine methyltransferases: Structure, specificity and catalysis[J]. Cell Mol Life Sci,2006,63(23) :2755-2763.
  • 10Aravind L, Iyer L M. Provenance of SET domain histone methyltransferases through duplication of a simple structural unit[J]. Cell Cycle, 2003,2 (4) : 369-376.

共引文献22

同被引文献20

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部